Literature DB >> 21084478

Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function.

Meika Richmond1, Lyle R McKinnon, Sandra A Koesters Kiazyk, Charles Wachihi, Makobu Kimani, Joshua Kimani, Francis A Plummer, T Blake Ball.   

Abstract

The limited success of HIV vaccine candidates to date highlights our need to better characterize protective cell-mediated immunity (CMI). While HIV-specific CD8(+) T cell responses have been defined largely by measuring gamma interferon (IFN-γ), these responses are not always protective, and it is unclear whether the same epitopes would predominate if other functional parameters were examined. Here, we assessed the epitope specificity of HIV-specific CD8(+) T cell responses by multiparametric flow cytometry, measuring five CD8(+) T cell functions (IFN-γ, macrophage inflammatory protein 1β [MIP-1β], tumor necrosis factor alpha [TNF-α], interleukin-2 [IL-2], and proliferative capacity) in 24 chronically HIV-infected individuals. Sixty-nine epitope-specific responses to 50 epitopes within p24 were measured. Surprisingly, most epitope-specific responses were IFN-γ negative (50/69 responses). Many responses had polyfunctional (33%) and proliferative (19%) components. An inverse association between IL-2 and proliferation responses was also observed, contrary to what was described previously. We confirm that long-term nonprogressors (LTNP) have more polyfunctional responses and also have higher-magnitude and broader p24-specific proliferation and higher levels of IL-2 and TNF-α production than do progressing controls. Together, these data suggest that the specificity of CD8(+) T cell responses differs depending on the immunological readout, with a 3.5-fold increase in breadth detected by including multiple parameters. Furthermore, the identification of epitopes that elicit polyfunctional responses reinforces the need for the comprehensive evaluation of HIV vaccine candidates, and these epitopes may represent novel targets for CMI-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084478      PMCID: PMC3020503          DOI: 10.1128/JVI.01707-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level.

Authors:  A L Erickson; C B Willberg; V McMahan; A Liu; S P Buchbinder; L A Grohskopf; R M Grant; D F Nixon
Journal:  Clin Vaccine Immunol       Date:  2008-09-24

2.  Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.

Authors:  Scott G Hansen; Cassandra Vieville; Nathan Whizin; Lia Coyne-Johnson; Don C Siess; Derek D Drummond; Alfred W Legasse; Michael K Axthelm; Kelli Oswald; Charles M Trubey; Michael Piatak; Jeffrey D Lifson; Jay A Nelson; Michael A Jarvis; Louis J Picker
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

3.  The role of IFN-gamma Elispot assay in HIV vaccine research.

Authors:  Hendrik Streeck; Nicole Frahm; Bruce D Walker
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

4.  Substantial intrapatient differences in the breadth and specificity of HIV-specific CD8+ T-cell interferon-gamma and proliferation responses.

Authors:  Lyle R McKinnon; T Blake Ball; Charles Wachihi; Nyakio Chinga; Anne Maingi; Ma Luo; Keith R Fowke; Francis A Plummer
Journal:  J Acquir Immune Defic Syndr       Date:  2008-10-01       Impact factor: 3.731

Review 5.  Impact of MHC class I diversity on immune control of immunodeficiency virus replication.

Authors:  Philip J R Goulder; David I Watkins
Journal:  Nat Rev Immunol       Date:  2008-08       Impact factor: 53.106

6.  Proliferation, but not interleukin 2 production, of Gag-specific CD8+ T cells is associated with low HIV viremia and high CD4 counts in HIV-1-infected Chinese individuals.

Authors:  Haiying Li; Xinyue Chen; Xia Jin; Zhiying Liu; Xiaojie Huang; Zhenhuan Cao; Caiping Guo; Tao Dong; Hao Wu
Journal:  J Acquir Immune Defic Syndr       Date:  2009-09-01       Impact factor: 3.731

7.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

8.  Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity.

Authors:  Michael S Bennett; Hwee L Ng; Ayub Ali; Otto O Yang
Journal:  J Infect Dis       Date:  2008-02-01       Impact factor: 5.226

9.  Epitope mapping of HIV-specific CD8+ T cells in a cohort dominated by clade A1 infection.

Authors:  Lyle R McKinnon; Xiaojuan Mao; Joshua Kimani; Charles Wachihi; Christina Semeniuk; Mark Mendoza; Binhua Liang; Ma Luo; Keith R Fowke; Francis A Plummer; T Blake Ball
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

10.  Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells.

Authors:  Hendrik Streeck; Zabrina L Brumme; Michael Anastario; Kristin W Cohen; Jonathan S Jolin; Angela Meier; Chanson J Brumme; Eric S Rosenberg; Galit Alter; Todd M Allen; Bruce D Walker; Marcus Altfeld
Journal:  PLoS Med       Date:  2008-05-06       Impact factor: 11.069

View more
  8 in total

1.  Identification of Novel Respiratory Syncytial Virus CD4+ and CD8+ T Cell Epitopes in C57BL/6 Mice.

Authors:  Megan E Schmidt; Steven M Varga
Journal:  Immunohorizons       Date:  2019-01-14

2.  Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects.

Authors:  Missa P Sanou; Shannon R Roff; Antony Mennella; John W Sleasman; Mobeen H Rathore; Janet K Yamamoto; Jay A Levy
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

3.  Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.

Authors:  Rosamund Chapman; Enid Shephard; Helen Stutz; Nicola Douglass; Vasan Sambandamurthy; Irene Garcia; Bernhard Ryffel; William Jacobs; Anna-Lise Williamson
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

4.  Human CD4+ T Helper Cell Responses after Tick-Borne Encephalitis Vaccination and Infection.

Authors:  Judith H Aberle; Julia Schwaiger; Stephan W Aberle; Karin Stiasny; Ondrej Scheinost; Michael Kundi; Vaclav Chmelik; Franz X Heinz
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

Review 5.  The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis.

Authors:  Shannon R Roff; Ezra N Noon-Song; Janet K Yamamoto
Journal:  Front Immunol       Date:  2014-01-13       Impact factor: 7.561

6.  Fragmentation of SIV-gag vaccine induces broader T cell responses.

Authors:  Adel Benlahrech; Andrea Meiser; Shanthi Herath; Timos Papagatsias; Takis Athanasopoulos; Fucheng Li; Steve Self; Veronique Bachy; Catherine Hervouet; Karen Logan; Linda Klavinskis; George Dickson; Steven Patterson
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

7.  Broadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvant.

Authors:  Karen S Korsholm; Ingrid Karlsson; Sheila T Tang; Lea Brandt; Else Marie Agger; Claus Aagaard; Peter Andersen; Anders Fomsgaard
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

8.  Interferon gamma (IFN-γ) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens.

Authors:  Ritah Nakiboneka; Susan Mugaba; Betty O Auma; Christopher Kintu; Christina Lindan; Mary Bridget Nanteza; Pontiano Kaleebu; Jennifer Serwanga
Journal:  Vaccine       Date:  2018-11-17       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.